i
Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink
-
10 13 2017
Source: Vaccine. 35(43):5756-5758 -
Alternative Title:Vaccine
-
Personal Author:
-
Corporate Authors:
-
Description:Objective:
Describe the Vaccine Safety Datalink’s (VSD) Guillain Barré Syndrome (GBS) surveillance following quadrivalent HPV vaccine (4vHPV) from 2006 through 2015.
Methods:
Among 4vHPV vaccinated persons aged 9–26, ICD-9 coded GBS was identified in VSD’s electronic data. Medical records were reviewed and adjudicated to confirm GBS. We calculated incidence rates of confirmed GBS within 1–42 days following 4vHPV with a one-sided 95% confidence interval.
Results:
Following 2,773,185 4vHPV doses, we confirmed 1 case of GBS in a male and no cases among females. The incidence rate of medical record confirmed GBS within 42 days following 4vHPV vaccine was 0.36 cases per million 4vHPV doses administered (1-sided 95% CI 1.71), which was less than the background rate.
Conclusion:
We found no evidence of an increased risk of GBS following 4vHPV. With an upper 95% confidence limit, we estimate that, if an increased risk exists, we would expect at most 1.08 additional cases of GBS per million people vaccinated with 4vHPV.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:28935469
-
Pubmed Central ID:PMC6719547
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: